Outsourced Pharma Capacity Update Videos - Large Molecule

  1. Mabion Capacity Update January 2025: Large Molecule Development 1/28/2025

    Go on a virtual tour of our GMP-certified facility, where we uphold our expanded capabilities for large molecule development to the highest standards for clinical and commercial manufacturing.

  2. KBI Biopharma Capacity Update January 2025: Large Molecule Development 1/28/2025

    Follow along as Derek Ryan, Sr. Director of Analytical Development, showcases our high-throughput technology and digital tools for process understanding and optimizing decision-making.

  3. Cytovance Biologics Capacity Update January 2025: Large Molecule Development 1/28/2025

    Join Rose Rhomberg, Senior Business Development Director, as she showcases Cytovance’s microbial and mammalian capabilities, along with our available manufacturing capacity.

  4. Catalent Capacity Update January 2025: Large Molecule Development 1/28/2025

    Learn how our expertise and advanced capabilities provide customized analytical solutions that ensure quality, precision, and regulatory compliance for your biotherapeutics.

  5. Northway Biotech Capacity Update October 2024: Large Molecule Drug Substance 10/22/2024

    We have the capabilities, competitive advantages, and capacity to onboard new projects across two facilities: Waltham, MA, operational since 2020, and Vilnius, Lithuania, established in 2004.

  6. Cytovance Biologics Capacity Update October 2024: Large Molecule Drug Substance 10/22/2024

    Senior Business Development Director Rose Rhomberg presents an in-depth look at Cytovance’s capabilities and highlights the available capacity designed to accelerate your goals.

  7. Novartis Contract Manufacturing Capacity Update October 2024: Large Molecule Drug Substance 10/22/2024

    Gain valuable insights into our mammalian development services, manufacturing solutions, upcoming capacity availability, as well as updates on expansion timelines for external clients.

  8. Pfizer CentreOne Capacity Update October 2024: Large Molecule Drug Substance 10/22/2024

    See how our specialized manufacturing site in Sanford, NC — backed by over 35 years of expertise in mAb production — can expedite the delivery of your groundbreaking therapies to patients.

  9. Resilience Capacity Update October 2024: Large Molecule Drug Substance 10/22/2024

    Business Head of Biologics and Vaccines Evan Pasenello shares how Resilience’s innovative platforms and specialized expertise can effectively support your development and manufacturing programs.

  10. Boehringer Ingelheim BioXcellence™ Capacity Update October 2024: Large Molecule Drug Substance 10/22/2024

    Explore our global production network, advanced aseptic filling, in-house analytics, and the expertise that has driven 47 biopharmaceuticals to market success.